Abstracts Archive - Page 2116 of 2425 - ACR Meeting Abstracts

Abstract Number: 2043 • 2013 ACR/ARHP Annual Meeting
Perinatal Exposure To Traditional and Biologic Disease Modifying Antirheumatic Drugs In Rheumatic Diseases: A Systematic Review Of Congenital Outcomes
Corisande Baldwin¹, Sharan Rai², J. Antonio Avina-Zubieta^2,3 and Mary De Vera^2,4, ¹Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Despite the high incidence of rheumatic diseases during reproductive years, little is known about the perinatal impact of traditional and biologic disease modifying antirheumatic…
Abstract Number: 2044 • 2013 ACR/ARHP Annual Meeting
Birth Outcomes In Childbearing Women Treated With Thiopurines: A Meta-Analysis
Zeinab F. Saleh¹, Raveendhara R. Bannuru², William F. Harvey² and Timothy E. McAlindon³, ¹Adult Rheumatology, Tufts Medical Center, Boston, MA, ²Rheumatology, Tufts Medical Center, Boston, MA, ³Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: The thiopurines azathioprine (AZA) and 6-mercaptopurine (6-MP) are effective treatments for many rheumatic and autoimmune conditions. These medications have a category D classification from…
Abstract Number: 2045 • 2013 ACR/ARHP Annual Meeting
Long QT and Hydroxychloroquine; A Poorly Recognised Problem In Rheumatology Patients
Andra Negoescu¹, Andrew Thornback², Eugene Wong² and Andrew J. Ostor², ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom
Background/Purpose: Hydoxychloroquine (HCQ) is widely used for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) with a side-effect profile including myopathy…
Abstract Number: 2046 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Efficacy In Acute Pain: Results From Two Phase 3 Studies
Roy D. Altman¹, Allan Gibofsky², Mark Jaros³ and Clarence Young⁴, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³Summit Analytical, Denver, CO, ⁴Iroko Pharmaceuticals, Philadelphia, PA
Background/Purpose: Indomethacin is used to treat acute gouty arthritis and other acute pain conditions but, like other NSAIDs, is associated with dose-related gastrointestinal, cardiovascular, and…
Abstract Number: 2047 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Combined Safety From Two Phase 3 Studies In Patients With Acute Pain Following Elective Surgery
Allan Gibofsky¹, Roy D. Altman², Clarence Young³, Daniel Solorio⁴ and Jennifer Nezzer⁵, ¹Medicine and Public Health, Hospital for Special Surgery, New York, NY, ²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³Iroko Pharmaceuticals, Philadelphia, PA, ⁴Iroko Pharmaceuticals, LLC, Philadelphia, PA, ⁵Premier Research, Philadelphia, PA
Background/Purpose: Indomethacin is prescribed to treat acute pain and inflammation but, like other NSAIDs, is associated with dose-dependent gastrointestinal, cardiovascular, and renal adverse events (AEs).…
Abstract Number: 2048 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases
Takayuki Katsuyama¹, Sayaka Aoki², Ken-ei Sada³, Yuriko Yamamura¹, Haruki Watanabe¹, Eri Katsuyama¹, Mariko Narazaki¹, Noriko Tatebe¹, Koichi Sugiyama¹, Katsue S. Watanabe³, Hiroshi Wakabayashi¹, Tomoko Kawabata¹, Jun Wada⁴ and Hirofumi Makino³, ¹Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, ²Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Background/Purpose: Since the efficacy of glucocorticoids for various rheumatic diseases was reported, glucocorticoids are still one of the important therapeutic agents in the current treatment…
Abstract Number: 2009 • 2013 ACR/ARHP Annual Meeting
Outcome Of Allopurinol Or Febuxostat Treatment In Gout Patients Naïve To Urate-Lowering Therapy
Puja Khanna¹, Hind Hatoum^2,3, Swu-Jane Lin^2,4, Aki Shiozawa⁵, Kasem Akhras⁶ and Dinesh Khanna¹, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Hind T. Hatoum and Company, Chicago, IL, ³University of Illinois at Chicago, chicago, IL, ⁴University of Illinois at Chicago, Chicago, IL, ⁵Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁶Global Outcomes Research, Formerly of Takeda Pharmaceuticals International, Inc, Deerfield, IL
Background/Purpose: In the US, 3.9% (8.3 million) of the population have self-reported gout, and 21.4% (43.3 million) have hyperuricemia. The 2012 ACR guidelines recommend febuxostat…
Abstract Number: 2010 • 2013 ACR/ARHP Annual Meeting
Erdheim-Chester Disease: A Monocentric Series Of 96 Patients
Julien Haroche¹, Laurent Arnaud¹, Fleur Cohen-Aubart¹, Baptiste Hervier¹, David Saadoun¹, Nathalie Costedoat-Chalumeau², Sophie Besnard³, Kim Heang Ly⁴, Michel Pavic⁵, Jean-Gabriel Fuzibet⁶, Loic Raffray⁷, Laurent Aaron⁸, Pascal Bindi⁹, António Marinho¹⁰, Bjorn Blomberg¹¹, Juan Salvatierra¹², Claudia Dechant¹³, Aude Rigolet¹⁴, François Lifermann¹⁵, Jo Caers¹⁶, Catherine Veyssier-Belot¹⁷, Bertrand Wechsler¹⁸, Lucienne Michaux¹⁹, Giorgio Graziani²⁰ and Zahir Amoura¹, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal Medicine, Hopital Cochin, Paris, France, ³Internal Medicine, Pontchaillou University Hospital, Rennes, Rennes, France, ⁴CHU Dupuytren, Limoges, Limoges, France, ⁵Internal Medicine, HIA Desgenettes, Lyon, France, Lyon, France, ⁶Internal Medicine, Internal Medicine, Hôpital de l'Archet 1, CHU de Nice, Nice, France, ⁷Internal Medicine, CHU de Bordeaux, Bordeaux, France, ⁸Internal Medicine, Hôpital Jacques Coeur, Bourges, Bourges, France, ⁹Internal Medicine, Department of medicine A, Centre Hospitalier de Verdun, Verdun, France, ¹⁰Unidade de Imunologia Clínica, Porto, Portugal, ¹¹Internal Medicine, University of Bergen, Norway, Bergen, France, ¹²Rheumatology, University Hospital San Cecilio, Granada, Spain, ¹³Division of Rheumatology and Clinical Immunology, Med. Klinik und Poliklinik IV, University of Munich, Munich, Germany, ¹⁴Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ¹⁵Internal Medicine, CH Côte d'Argent, Dax, Dax, France, ¹⁶Department of Clinical Hematology, Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman, Liège, Belgium, ¹⁷Internal Medicine, CHI Poissy Saint-Germain-en-Laye, Saint-Germain-en-Laye, France, ¹⁸Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁹Hematology, Cliniques Universitaires Saint-Luc UCL Bruxelles, Bruxelles, Belgium, ²⁰Internal Medicine and Nephrology, Istituto Clinico Humanitas IRCCS, Rozzano-Milano, Italy, Milan, Italy
Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans form of histiocytosis characterized by an infiltration of foamy CD68+ CD1a- histiocytes. More than 500 cases of…
Abstract Number: 2011 • 2013 ACR/ARHP Annual Meeting
Osseous Sarcoidosis: Clinical Presentation, Treatment, and Outcomes. Experience From a Large Tertiary Care Academic Hospital
Jeffrey A. Sparks¹, Jakob I. McSparron², Christopher H. Fanta² and Jonathan S. Coblyn³, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by the formation of non-caseating granulomas. Osseous involvement in sarcoidosis is a rare manifestation and has infrequently…
Abstract Number: 2012 • 2013 ACR/ARHP Annual Meeting
Gender Influences On Organ Manifestations In a New Orleans Sarcoidosis Population
Adam Janot¹, McCall Walker², Mary Yu¹, Harmanjot K. Grewal³, Matthew R. Lammi^4,5 and Lesley Ann Saketkoo^6,7, ¹Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²LSUHSC School of Medicine, New Orleans, LA, ³Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ⁴Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁵Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁶LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁷Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Sarcoidosis is a multi-organ disease in which pulmonary manifestations predominate. The skin, eyes, heart, gastrointestinal tract (GI), reticuloendothelial, renal and nervous systems are also…
Abstract Number: 2013 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy In Refractory Uveitis Of Sarcoidosis. Multicenter Study Of 16 Patients
Javier Loricera¹, Vanesa Calvo-Río², Ricardo Blanco³, Marina Mesquida⁴, Alfredo M. Adan⁴, JM Herreras⁵, A Aparicio⁶, MJ Moreno Ramos⁷, MJ Moreno Martínez⁷, LF Linares Ferrando⁷, M Hernández Martínez⁸, D Peitado-Lopez⁹, Miguel Cordero-Coma¹⁰, Jl García Serrano¹¹, Norberto Ortego¹¹, O Maíz¹², A Blanco¹³, Juan Sánchez-Bursón¹⁴, S González-Suárez¹⁵, Alejandro Fonollosa¹⁶, Montserrat Santos-Gómez², F. Ortiz-Sanjuán¹ and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Marques de Valdecilla, Santander, Spain, ⁴Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁵Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, ⁶Rheumatology., Hospital de Toledo., Toledo, Spain, ⁷Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ⁸Ophthalmology, Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ⁹Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, ¹⁰Ophthalmology, Hospital de León. Spain, León, Spain, ¹¹Hospital San Cecilio. Granada, Granada, Spain, ¹²Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, ¹³Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁴Hospital de Valme. Sevilla, Sevilla, Spain, ¹⁵Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, ¹⁶Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain
Background/Purpose: Uveitis related to sarcoidosis is a potentially severe complication. Corticosteroids are the first line of treatment. In refractory cases or in those with unacceptable…
Abstract Number: 2014 • 2013 ACR/ARHP Annual Meeting
Cigarette Smoking and Male Sex Are Independent Risk Factors For Ocular Sarcoidosis
Adam Janot¹, Dörte Huscher², McCall Walker³, Harmanjot K. Grewal⁴, Mary Yu¹, Matthew R. Lammi^5,6 and Lesley Ann Saketkoo^7,8, ¹Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³LSUHSC School of Medicine, New Orleans, LA, ⁴Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ⁵Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁷LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁸Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Sarcoidosis is a multi-organ system granulomatous disease of unknown origin with an incidence of 1-40/100,000. Though pulmonary manifestations are predominant, ocular morbidity is characteristic. …
Abstract Number: 2015 • 2013 ACR/ARHP Annual Meeting
Sarcoid Arthritis In World Trade Center Exposed New York City Firefighters Presenting As a Unique Clinical Subset
Konstantinos Loupasakis¹, Jessica Berman², Michelle S Glaser^3,4, Nadia Jaber⁴, Rachel Zeig-Owens^3,4, Mayris P Webber^4,5, Michael D Weiden^4,6, Anna Nolan^4,7, Kerry J Kelly⁴ and David J Prezant^4,8, ¹Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ²Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ³Medicine, Montefiore Medical Center, Bronx, NY, ⁴Bureau of Health Services Fire Department of New York, Brooklyn, NY, ⁵Medicine and Epideiology and Population Health, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, ⁶Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, New York, NY, ⁷Medicine, New York University School of Medicine, New York, NY, ⁸Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Sarcoidosis is a multisystem disease characterized by the formation of non-caseating granulomas with lungs being predominantly affected and the joints in up to 40%.…
Abstract Number: 2016 • 2013 ACR/ARHP Annual Meeting
Inflamamatory Myositis-Increased Incidence In Fire Department Of New York Firefighters After World Trade Center Exposure
Basit Qayyum¹, Michelle S Glaser^2,3, Nadia Jaber³, Rachel Zeig-Owens^2,3, Mayris P Webber^3,4, Anna Nolan^3,5, Kerry J Kelly³ and David J Prezant^3,6, ¹New York University School of Medicine, New York, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Bureau of Health Services Fire Department of New York, Brooklyn, NY, ⁴Medicine and Epideiology and Population Health, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, ⁵Medicine, New York University School of Medicine, New York, NY, ⁶Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Inflammatory myositis (IM) is extremely rare in white middle-aged males. Incidence rates in males ranging from 0.25 to 5 per million. We describe a…
Abstract Number: 2017 • 2013 ACR/ARHP Annual Meeting
Hyper Ferritinemia Suggests a High Frequency Of Macrophage Activation Syndrome In a Large Adult Severe Sepsis Cohort: A Role For Anakinra?
Bita Shakoory¹, Joseph A. Carcillo² and Steven Opal³, ¹Medicine/Rheumatology, Temple University, Philadelphia, PA, ²Pediatrics, University of Pittsburg Medical Center, Pittsburgh, PA, ³Medicine, Brown University, Providence, RI
Background/Purpose: Inreased ferritin levels are protective during infection whereas but very very high level are associated with MAS in rheumatologic disease cTo determine frequency of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].